Rock Creek Pharmaceuticals received IRB approval of the first human clinical study of the safety and effects of nutritional supplementation with Anatabloc® in individuals with Alzheimer's disease in April 2012. The study is being conducted in conjunction with the Roskamp Institute of Sarasota, Florida, which has been acting as a research partner in assessing the impact of Anatabloc® on Alzheimer's. In addition to the Roskamp Institute site, the study also is being conducted at the Beaumont Hospital in Royal Oak, Michigan. Dr. Michael Mullan, M.D., Ph.D., President and CEO of the Roskamp Institute, commented: "We have known for a long time that Alzheimer's disease has a large inflammatory component. We also have observed the anti-inflammatory effects of anatabine (the active ingredient of Anatabloc®) in laboratory tests which is why we anticipate evidence of anti-inflammatory effects in this population."
, M.D., M.P.H, Medical Director for Rock Creek Pharmaceuticals, said, "It is our profound hope that appropriate nutritional supplementation will be of some benefit to conventional care in the population suffering from this terrible disease. When we received the initial reports of beneficial responses in individuals, we realized that it was essential to determine if such reports represented a real beneficial nutritional effect. This study is the first one that will confirm or refute a significant nutritional effect of Anatabloc® in this population."
Individuals interested in the RCP-009 study can learn more by contacting the Roskamp Institute in
Certain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials, the challenges inherent in new product development initiatives, including the continued development and market acceptance of our nutraceutical and low-TSNA tobacco products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, including with respect to our nutraceutical and low-TSNA tobacco products, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our annual report on Form 10-K for the fiscal year ended
December 31, 2011
. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.
About Star Scientific
Star Scientific, Inc. is a technology-oriented company with a mission to promote maintenance of a healthy metabolism, as well as to reduce the harm associated with the use of tobacco at every level. Over the last several years, through its wholly owned subsidiary, Rock Creek Pharmaceuticals, Star Scientific has been engaged in the manufacturing, sale, and marketing of two nutraceutical dietary supplements, and the development of other nutraceuticals and pharmaceuticals. The company also has continued to pursue the development, implementation, and licensing of the technology behind its proprietary StarCured® tobacco curing process, which substantially prevents the formation of carcinogenic toxins present in tobacco and tobacco smoke, primarily the tobacco-specific nitrosamines, or TSNAs and related low-TSNA dissolvable tobacco products. Rock Creek Pharmaceuticals has scientific and research offices in
, and a regulatory office in
. Star Scientific has a Corporate and Sales Office in
Glen Allen, VA
; Executive, Scientific & Regulatory Affairs offices in
; and a manufacturing facility in
Chase City, VA
Talhia T. Tuck
Vice President, Communications and Investor Relations Star Scientific, Inc. (301) 654-8300